CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Given Average Rating of “Moderate Buy” by Brokerages

Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) have earned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $14.57.

CBAY has been the topic of several recent research reports. BTIG Research initiated coverage on CymaBay Therapeutics in a report on Thursday, March 9th. They set a “buy” rating and a $15.00 price objective on the stock. StockNews.com lowered CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, May 15th. SVB Leerink raised their target price on CymaBay Therapeutics from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 8th. Piper Sandler raised their target price on CymaBay Therapeutics from $12.00 to $19.00 and gave the stock an “overweight” rating in a research report on Sunday, January 29th. Finally, Oppenheimer raised their target price on CymaBay Therapeutics from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 7th.

Insider Buying and Selling at CymaBay Therapeutics

In other CymaBay Therapeutics news, General Counsel Paul T. Quinlan sold 5,000 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $10.37, for a total transaction of $51,850.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, General Counsel Paul T. Quinlan sold 5,000 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $10.37, for a total value of $51,850.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dennis D. Kim sold 7,781 shares of the stock in a transaction on Thursday, April 13th. The stock was sold at an average price of $8.98, for a total value of $69,873.38. Following the completion of the sale, the insider now owns 20,000 shares in the company, valued at approximately $179,600. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 146,849 shares of company stock valued at $1,390,672. Company insiders own 5.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. CM Management LLC grew its stake in shares of CymaBay Therapeutics by 60.0% in the fourth quarter. CM Management LLC now owns 160,000 shares of the biopharmaceutical company’s stock worth $1,003,000 after purchasing an additional 60,000 shares during the last quarter. Strategic Blueprint LLC purchased a new stake in CymaBay Therapeutics in the third quarter worth about $64,000. Bank of Montreal Can purchased a new stake in CymaBay Therapeutics in the fourth quarter worth about $354,000. LPL Financial LLC lifted its holdings in CymaBay Therapeutics by 21.6% in the fourth quarter. LPL Financial LLC now owns 116,213 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 20,619 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in CymaBay Therapeutics by 9.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 290,174 shares of the biopharmaceutical company’s stock worth $1,819,000 after buying an additional 25,112 shares during the period. 73.54% of the stock is owned by institutional investors.

CymaBay Therapeutics Price Performance

Shares of NASDAQ:CBAY opened at $9.11 on Monday. The company has a market capitalization of $888.32 million, a P/E ratio of -7.72 and a beta of 0.27. CymaBay Therapeutics has a 1 year low of $1.81 and a 1 year high of $11.22. The business’s 50 day simple moving average is $9.51 and its 200 day simple moving average is $7.24.

CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) last issued its quarterly earnings results on Thursday, March 16th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.30). During the same period last year, the company posted ($0.34) EPS. On average, sell-side analysts anticipate that CymaBay Therapeutics will post -1.01 EPS for the current fiscal year.

About CymaBay Therapeutics

(Get Rating)

CymaBay Therapeutics, Inc engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.